Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Malignant Mesothelioma Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The malignant mesothelioma market size has experienced strong growth in recent years. It is forecast to expand from $2.61 billion in 2025 to $2.77 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.3%. This historical expansion can be attributed to several factors, including past asbestos exposure in construction and manufacturing, the long disease latency period, limited early treatment options, a rise in occupational health awareness, and the gradual improvement of diagnostic imaging.
The malignant mesothelioma market is anticipated to show robust expansion in the coming years. It is projected to achieve a value of $3.53 billion by 2030, progressing at a compound annual growth rate (CAGR) of 6.3%. This forecasted growth can be linked to breakthroughs in immunotherapy and targeted medications, increased funding for rare cancer research, an expanding volume of clinical trials, enhanced diagnostic tools, and a rise in healthcare spending on oncology. Significant patterns expected during this period involve the wider adoption of immunotherapy and targeted treatment, a greater emphasis on integrated treatment methods, an increasing requirement for prompt and precise diagnosis, the growth of specialized mesothelioma care facilities, and enhanced involvement in clinical trials for uncommon cancers.
Get A Free Sample Report With In-Depth Market Insights:
Malignant Mesothelioma Market Growth Momentum: What Factors Are Shaping Demand?
The malignant mesothelioma market is anticipated to expand due to rising clinical research and development endeavors. These R&D efforts encompass scientific investigations and trials aimed at creating novel pharmaceuticals, therapies, and medical devices, involving the evaluation of their safety, effectiveness, and possible adverse reactions via regulated clinical trials. The surge in clinical R&D stems from an increasing need for enhanced and innovative treatments, particularly given the growing incidence of chronic ailments and intricate health issues. R&D initiatives propel advancements in the malignant mesothelioma domain by fast-tracking diagnostics, treatments, and precise therapies, thereby promoting inventive strategies for better early identification, improved survival outcomes, and the creation of more potent, less intrusive treatment alternatives. As an illustration, in January 2025, Anadolu Agency, a state-run news agency from Turkey, reported that clinical trials constitute almost 40% of the pharmaceutical research budget in the U.S., amounting to about $7 billion each year. Consequently, the escalation in research and development activities is fueling the expansion of the malignant mesothelioma market.
Malignant Mesothelioma Market Segmentation And Category Overview
The malignant mesothelioma market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy
2) By Route Of Administration: Oral, Intravenous, Injectable
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
4) By End-User: Hospitals, Oncology Clinics
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches
Malignant Mesothelioma Market Trends Redefining Industry Growth
Leading companies in the malignant mesothelioma market are concentrating on developing advanced treatment options, such as monoclonal antibody therapies, to curb tumor growth and enhance treatment accuracy. Monoclonal antibodies are laboratory-produced proteins designed to imitate the immune system’s capacity to identify and target specific antigens, including those found on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, obtained supplemental approval in Japan for the expanded application of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody, for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval positions Opdivo as a new therapeutic alternative for this condition, for which no established standard treatments existed previously. Opdivo was also granted orphan drug designation for this indication, emphasizing its potential to address a significant medical necessity.
Malignant Mesothelioma Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.
View The Full Malignant Mesothelioma Market Report:
Malignant Mesothelioma Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
